AstraZeneca discută preluarea companiei americane Bristol Myers Squibb

AstraZeneca and Bristol Myers Squibb are in talks for a potential merger that could create a major pharmaceutical entity valued at around $400 billion. Discussions have been ongoing for months, but no final agreement is guaranteed. The merger could enhance AstraZeneca's position in the U.S. market, although regulatory challenges may arise due to overlapping oncology portfolios. Analysts note that while the merger could lead to significant cost savings, past pharmaceutical megamergers have often slowed drug development.